Funding
Funding not disclosed
Founders
Product
Problem
Bacterial and parasitic diseases pose significant threats to animal health, human food safety, and can lead to zoonotic diseases. Current solutions, such as antibiotics, are becoming less effective due to increasing antimicrobial resistance, creating an urgent need for alternative preventative measures. Existing vaccines often lack broad-spectrum protection and can be costly to produce, limiting their accessibility, especially in the animal vaccine market.
Solution
Malcisbo AG develops carbohydrate-based vaccines using a novel glycoengineering platform to combat bacterial and parasitic infections. Their technology focuses on identifying and targeting surface glycan structures on pathogenic bacteria. These glycans are then transplanted into a host bacterium, which serves as a cost-effective vaccine in the target animal species. This approach enables the creation of broad-spectrum vaccines that can reduce reliance on antibiotics in farming animals, thereby mitigating the spread of antimicrobial resistance and improving food safety.
Target Audience
The primary target audience includes farming animal sectors seeking to reduce antibiotic usage, as well as the veterinary pharmaceutical industry and organizations focused on improving human food safety and preventing zoonotic diseases.
Features
- Glycoengineering platform for identifying and targeting pathogenic surface glycan structures.
- Recombinant expression of specific sugar moieties on the surface of vector bacteria.
- Focus on developing vaccines against _Campylobacter_ colonization in chicken and _Actinobacillus pleuropneumoniae_ infection in pigs.
- Live, oral _Campylobacter_ vaccine using a _Salmonella_ based glycoconjugate.
- Prototype vaccine against _Actinobacillus pleuropneumoniae_ (APP) that resulted in reduced lung lesion scores in pigs.
- Glycoplatform technology applicable for a variety of bacterial diseases.